Department of Hematology and Oncology, Children's Hospital, Los Angeles, CA, United States.
Terasaki Foundation Laboratory, Santa Monica, CA, United States.
Front Immunol. 2021 Nov 22;12:667834. doi: 10.3389/fimmu.2021.667834. eCollection 2021.
Transplantation (Tx) remains the optimal therapy for end-stage disease (ESD) of various solid organs. Although alloimmune events remain the leading cause of long-term allograft loss, many patients develop innate and adaptive immune responses leading to graft tolerance. The focus of this review is to provide an overview of selected aspects of the effects of inflammation on this delicate balance following solid organ transplantation. Initially, we discuss the inflammatory mediators detectable in an ESD patient. Then, the specific inflammatory mediators found post-Tx are elucidated. We examine the reciprocal relationship between donor-derived passenger leukocytes (PLs) and those of the recipient, with additional emphasis on extracellular vesicles, specifically exosomes, and we examine their role in determining the balance between tolerance and rejection. The concept of recipient antigen-presenting cell "cross-dressing" by donor exosomes is detailed. Immunological consequences of the changes undergone by cell surface antigens, including HLA molecules in donor and host immune cells activated by proinflammatory cytokines, are examined. Inflammation-mediated donor endothelial cell (EC) activation is discussed along with the effect of donor-recipient EC chimerism. Finally, as an example of a specific inflammatory mediator, a detailed analysis is provided on the dynamic role of Interleukin-6 (IL-6) and its receptor post-Tx, especially given the potential for therapeutic interdiction of this axis with monoclonal antibodies. We aim to provide a holistic as well as a reductionist perspective of the inflammation-impacted immune events that precede and follow Tx. The objective is to differentiate tolerogenic inflammation from that enhancing rejection, for potential therapeutic modifications. (
移植(Tx)仍然是治疗各种实体器官终末期疾病(ESD)的最佳疗法。尽管同种免疫事件仍然是导致长期移植物丧失的主要原因,但许多患者会产生固有和适应性免疫反应,从而导致移植物耐受。本综述的重点是提供实体器官移植后炎症对这种微妙平衡影响的某些方面的概述。最初,我们讨论了 ESD 患者中可检测到的炎症介质。然后,阐明了 Tx 后发现的特定炎症介质。我们检查了供体来源的过客白细胞(PL)与受体之间的相互关系,并特别强调了细胞外囊泡,特别是外泌体,并检查了它们在确定耐受与排斥之间平衡中的作用。详细讨论了供体外泌体使受体抗原呈递细胞“变装”的概念。检查了细胞表面抗原(包括供体和受激炎性细胞因子激活的宿主免疫细胞中的 HLA 分子)发生的变化的免疫后果。讨论了炎症介导的供体细胞内皮细胞(EC)激活以及供体-受体 EC 嵌合体的作用。最后,作为特定炎症介质的一个例子,详细分析了 Tx 后白细胞介素 6(IL-6)及其受体的动态作用,特别是考虑到用单克隆抗体对此轴进行治疗干预的潜力。我们旨在提供一个整体的和简化的观点,即炎症影响的免疫事件,这些事件在 Tx 之前和之后都会发生。目的是区分诱导耐受的炎症与增强排斥的炎症,以进行潜在的治疗修改。